Letermovir
- Generic Name
- Letermovir
- Brand Names
- Prevymis
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28F4N4O4
- CAS Number
- 917389-32-3
- Unique Ingredient Identifier
- 1H09Y5WO1F
- Background
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status from the FDA. It is cur...
- Indication
Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in adult kidney transplant recipients who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegat...
- Associated Conditions
- Cytomegalovirus (CMV) Infections
- Associated Therapies
- -
Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- University College, London
- Target Recruit Count
- 36
- Registration Number
- NCT06626555
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 50
- Registration Number
- NCT06453460
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, United States
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06449586
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06441669
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 90
- Registration Number
- NCT06407232
- Locations
- 🇺🇸
UW Hospital and Clinics, Madison, Wisconsin, United States
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 80
- Registration Number
- NCT06334497
- Locations
- 🇫🇷
Hôpital Necker Enfants Malades, Paris, France
Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Cao Weijie
- Target Recruit Count
- 150
- Registration Number
- NCT06306989
- Locations
- 🇨🇳
Cao, Weijie, Zhengzhou, Henan, China
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 12
- Registration Number
- NCT06118515
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama, United States
🇺🇸Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington, District of Columbia, United States
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT05969743
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 21
- Registration Number
- NCT05914675
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.